Rossari Biotech Limited (NSE:ROSSARI)
India · Delayed Price · Currency is INR | Market Cap | 23.82B -32.8% |
| Revenue (ttm) | 26.61B +19.8% |
| Net Income | 1.53B +11.8% |
| EPS | 27.54 +11.6% |
| Shares Out | 55.39M |
| PE Ratio | 15.61 |
| Forward PE | 14.26 |
| Dividend | 0.50 (0.12%) |
| Ex-Dividend Date | Jul 10, 2026 |
| Volume | 37,966 |
| Open | 429.70 |
| Previous Close | 429.70 |
| Day's Range | 428.30 - 438.00 |
| 52-Week Range | 375.00 - 639.40 |
| Beta | 0.56 |
| Analysts | Buy |
| Price Target | 575.50 (+33.84%) |
| Earnings Date | Oct 17, 2026 |
About Rossari Biotech
Rossari Biotech Limited manufactures and sells specialty chemicals in India and internationally. It offers home, personal care, and performance chemicals products, such as soaps and detergents; oil and gas division; inks; paints and coatings; ceramics and tiles; pulp and paper; cement; water treatment; performance additives; cleaning, hygiene, and disinfection; surfactants; and textile specialty chemicals, such as cotton, polyester, acrylic, wool, silk, nylon, functional finishes, denim, printing, and sustainable solutions. The company also pro... [Read more]
Financial Performance
In fiscal year 2026, Rossari Biotech's revenue was 23.96 billion, an increase of 15.19% compared to the previous year's 20.80 billion. Earnings were 1.49 billion, an increase of 9.41%.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ROSSARI stock is "Buy." The 12-month stock price target is ₹575.50, which is an increase of 33.84% from the latest price.
News
Rossari Biotech Transcript: Q2 26/27
Q2 revenue and EBITDA reached quarterly records, with broad-based growth and improving sequential margins. Freight, raw-material volatility, EO constraints, and geopolitical disruption remain headwinds; FY27 EBITDA margin is guided at around 12%.
Rossari Biotech Slides: Q2 2027
Rossari Biotech has posted slides in relation to its Q2 2027 quarterly earnings report, which was published on October 19, 2026.
Rossari Biotech Quarterly report: Q2 2027
Rossari Biotech has published its Q2 2027 quarterly earnings report on October 19, 2026.
Rossari Biotech Transcript: Q1 26/27
Q1 FY 2027 saw record revenue and EBITDA, with 28% YoY growth driven by core B2B segments and international expansion. Margin improvement is expected as capacity utilization rises and non-core B2C businesses are exited, with a steady-state EBITDA margin target of 14-15% over two years.
Rossari Biotech Quarterly report: Q1 2027
Rossari Biotech has published its Q1 2027 quarterly earnings report on July 20, 2026.
Rossari Biotech Slides: Q1 2027
Rossari Biotech has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on July 20, 2026.
Rossari Biotech schedules 17th AGM for 20th July 2026
Rossari Biotech Limited has announced that its 17th Annual General Meeting (AGM) will be held on 20th July 2026 at 11:00 A.M. (IST) through Video Conferencing (VC) or Other Audio-Visual…
Rossari Biotech reports 31% export contribution to total turnover for FY2025-26
Rossari Biotech has released its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, highlighting significant contributions from its export operations. The report ...
Rossari Biotech's Unistar sets up 5000 MTPA blending facility in Thailand
Rossari Biotech has announced that its wholly-owned subsidiary, Unistar Thai Co. Limited, has established a new blending facility in Thailand. The facility boasts an installed capacity of 5000 metric ...
Rossari Biotech schedules 17th AGM on July 20, 2026, with dividend record date set
Rossari Biotech has announced the scheduling of its 17th Annual General Meeting (AGM) on Monday, July 20, 2026, at 11:00 A.M. (IST). The meeting will be conducted through Video Conference/Other…
Rossari Biotech Transcript: Q4 25/26
Q4 and FY 2026 saw record revenue and EBITDA, with 15% annual growth driven by all segments and strong exports. FY 2027 guidance targets similar or higher growth and 12%-13% EBITDA margins, supported by new capacities, product mix improvements, and cost optimization.
Rossari Biotech Quarterly report: Q4 2026
Rossari Biotech has published its Q4 2026 quarterly earnings report on April 28, 2026.
Rossari Biotech Slides: Q4 2026
Rossari Biotech has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on April 28, 2026.
Rossari Biotech Annual report: Q4 2026
Rossari Biotech has published its Q4 2026 annual report on April 28, 2026.
Rossari Biotech subsidiary approves Rs 10 crore sale of Mumbai office premises
Rossari Biotech's material subsidiary, Unitop Chemicals Private Limited, has approved the sale of its office premises located in Saki Naka, Mumbai. The transaction, valued at approximately ₹10 crores,...
Rossari Biotech Transcript: Q3 25/26
Q3 FY26 saw 13% YoY revenue growth, led by strong export performance and broad-based segment gains, though margins were impacted by ongoing investments and EO supply constraints. New capacity ramp-ups and international expansion, especially in Saudi Arabia, are expected to drive future growth.
Rossari Biotech Quarterly report: Q3 2026
Rossari Biotech has published its Q3 2026 quarterly earnings report on January 19, 2026.
Rossari Biotech Slides: Q3 2026
Rossari Biotech has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on January 19, 2026.
Rossari Biotech’s subsidiary wins GST appeal; previous tax order set aside
Rossari Biotech Limited has announced that its subsidiary, Unitop Chemicals Private Limited, has successfully won an appeal against a GST Order issued by the Joint Commissioner, Central GST & Central ...
Rossari Biotech stock drops 4.28% following Q2 results
Rossari Biotech saw its stock price fall by 4.28%, trading at ₹838.35 as of 9:35 AM today. The drop follows the company’s release of its Q2 FY24-25 earnings, which failed to meet market expectations. ...